ZA200503645B - Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds - Google Patents
Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compoundsInfo
- Publication number
- ZA200503645B ZA200503645B ZA200500364A ZA200503645A ZA200503645B ZA 200503645 B ZA200503645 B ZA 200503645B ZA 200500364 A ZA200500364 A ZA 200500364A ZA 200503645 A ZA200503645 A ZA 200503645A ZA 200503645 B ZA200503645 B ZA 200503645B
- Authority
- ZA
- South Africa
- Prior art keywords
- alpha
- diseases
- combinations
- compounds
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43252702P | 2002-12-11 | 2002-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200503645B true ZA200503645B (en) | 2006-11-29 |
Family
ID=32507947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200500364A ZA200503645B (en) | 2002-12-11 | 2005-05-06 | Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds |
Country Status (12)
Country | Link |
---|---|
US (1) | US20050245504A1 (de) |
EP (1) | EP1572205A2 (de) |
JP (1) | JP2006510662A (de) |
KR (1) | KR20050085535A (de) |
CN (1) | CN1726033A (de) |
AU (1) | AU2003279492A1 (de) |
BR (1) | BR0317110A (de) |
CA (1) | CA2508004A1 (de) |
MX (1) | MXPA05005666A (de) |
PL (1) | PL377777A1 (de) |
WO (1) | WO2004052348A2 (de) |
ZA (1) | ZA200503645B (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
GB0220581D0 (en) * | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
GB0310867D0 (en) * | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
ZA200603165B (en) | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
KR101099206B1 (ko) | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
KR101176670B1 (ko) | 2004-03-25 | 2012-08-23 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸, 및그의 제조법 및 용도 |
PE20060437A1 (es) * | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
CA2589102C (en) | 2004-11-02 | 2013-08-13 | Northwestern University | Pyridazine compounds and methods for using the compounds to treat inflammatory diseases |
GB0521508D0 (en) * | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525673D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
EP2015750A2 (de) | 2006-04-28 | 2009-01-21 | Northwestern University | Zusammensetzungen und behandlungen mit pyridazinverbindungen und cholisterinasehemmern |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
PT2889033T (pt) | 2008-11-19 | 2018-06-18 | Forum Pharmaceuticals Inc | Tratamento de sintomas negativos da esquizofrenia com (r)-7-cloro-n-(-quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida e sais farmacêuticos resultantes da mesma |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
US20100233156A1 (en) * | 2009-03-09 | 2010-09-16 | Georgetown University | Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors |
RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
CN102905532A (zh) | 2010-02-09 | 2013-01-30 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
EP2571874B1 (de) | 2010-05-17 | 2016-03-30 | Forum Pharmaceuticals Inc. | Kristalline form von (r)-7-chloro-n-(chinuclidin-3-yl)benzo[b]thiophen-2-carboxamid-hydrochlorid-monohydrat |
BR112013001939A2 (pt) * | 2010-07-26 | 2017-07-11 | Envivo Pharmaceuticals Inc | tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase |
US11325904B2 (en) | 2011-08-02 | 2022-05-10 | Buck Institute For Research On Aging | Tropinol esters and related compounds to promote normal processing of APP |
CA2850707C (en) * | 2011-10-03 | 2023-03-21 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2014144801A1 (en) | 2013-03-15 | 2014-09-18 | Agenebio Inc. | Methods and compositions for improving cognitive function |
WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
EP3623371A1 (de) * | 2014-12-16 | 2020-03-18 | Axovant Sciences GmbH | Geminale substituierte chinuklidinamidverbindungen als agonisten von alpha-7-nikotinischen acetylcholinrezeptoren |
EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
LT3324977T (lt) | 2015-07-22 | 2022-10-25 | Enanta Pharmaceuticals, Inc. | Benzodiazepino dariniai kaip rsv inhibitoriai |
RU2624978C2 (ru) * | 2015-07-27 | 2017-07-11 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ лечения умеренного когнитивного снижения |
UY38614A (es) | 2019-03-18 | 2020-10-30 | Enanta Pharm Inc | Derivados de benzodiazepinas como inhibidores del rsv |
CA3153297A1 (en) | 2019-10-04 | 2021-04-08 | Adam SZYMANIAK | Antiviral heterocyclic compounds |
US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
CN112625057B (zh) * | 2020-12-25 | 2022-12-09 | 山东金城柯瑞化学有限公司 | 3-羟基-4-((三甲基甲硅烷基)乙炔基)苯甲酸甲酯的合成方法 |
MX2023009961A (es) * | 2021-02-26 | 2023-09-05 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9904176D0 (sv) * | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
US6500840B2 (en) * | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
AU2001284646A1 (en) * | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
BR0209985A (pt) * | 2001-05-22 | 2004-06-29 | Elan Pharm Inc | Composto e método para o tratamento de um paciente |
US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
-
2003
- 2003-11-28 JP JP2004558917A patent/JP2006510662A/ja active Pending
- 2003-11-28 CN CNA2003801058118A patent/CN1726033A/zh active Pending
- 2003-11-28 AU AU2003279492A patent/AU2003279492A1/en not_active Abandoned
- 2003-11-28 EP EP03772599A patent/EP1572205A2/de not_active Withdrawn
- 2003-11-28 WO PCT/IB2003/005525 patent/WO2004052348A2/en not_active Application Discontinuation
- 2003-11-28 MX MXPA05005666A patent/MXPA05005666A/es unknown
- 2003-11-28 BR BR0317110-8A patent/BR0317110A/pt not_active Application Discontinuation
- 2003-11-28 KR KR1020057010585A patent/KR20050085535A/ko not_active Application Discontinuation
- 2003-11-28 CA CA002508004A patent/CA2508004A1/en not_active Abandoned
- 2003-11-28 PL PL377777A patent/PL377777A1/pl not_active Application Discontinuation
- 2003-12-09 US US10/731,565 patent/US20050245504A1/en not_active Abandoned
-
2005
- 2005-05-06 ZA ZA200500364A patent/ZA200503645B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA05005666A (es) | 2005-07-26 |
JP2006510662A (ja) | 2006-03-30 |
WO2004052348A2 (en) | 2004-06-24 |
US20050245504A1 (en) | 2005-11-03 |
AU2003279492A1 (en) | 2004-06-30 |
EP1572205A2 (de) | 2005-09-14 |
CA2508004A1 (en) | 2004-06-24 |
BR0317110A (pt) | 2005-10-25 |
PL377777A1 (pl) | 2006-02-20 |
WO2004052348A3 (en) | 2004-10-21 |
CN1726033A (zh) | 2006-01-25 |
KR20050085535A (ko) | 2005-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200503645B (en) | Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds | |
AU2003223579A8 (en) | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease | |
TWI340640B (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
HK1079789A1 (zh) | 血管靜態毒性試劑及其使用方法 | |
EP1416961A4 (de) | Zusammensetzung und verfahren zur behandlung von krankheiten | |
AU2003273300A8 (en) | Modified glp-1 receptor agonists and their pharmacological methods of use | |
AU2003213673A8 (en) | Pin1-modulating compounds and methods of use thereof | |
EP1570839A4 (de) | Zusammensetzungzur herstellung zur äusserlichen anwendung auf der haut sowie verfahren zuihrer verwendung | |
AU2003246102A8 (en) | Method of examining allergic disease and drug for treating the same | |
EP1560593A4 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
EP1487446A4 (de) | Bicyclische heterocyclen zur behandlung von diabetes und anderen erkrankungen | |
AU2003268531A8 (en) | Materials and methods for treatment of allergic diseases | |
AU2003279442A8 (en) | 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes | |
AU2003290605A8 (en) | Compositions and methods for the diagnosis and treatment of sepsis | |
EP1572741A4 (de) | Therapeutische und diagnostische mittel | |
EP1476150A4 (de) | Carboxyfullerene und verwendungsverfahren dafür | |
AU2003268295A8 (en) | "diagnosis and treatment of infertility" | |
GB0212405D0 (en) | Composition and its therapeutic use | |
EP1575497A4 (de) | Neue zusammensetzung und verfahren zur behandlung von psoriasis | |
GB0207410D0 (en) | Compounds and their therapeutic use | |
PL375564A1 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
EP1545287A4 (de) | Vasoregulierende verbindungen und anwendungsverfahren | |
IL162941A0 (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases | |
AU2003244132A8 (en) | Method of examining allergic disaese and drug for treating the same | |
GB0207409D0 (en) | Benzofuran-2H-3-one compounds and their therapeutic use |